Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Invokana canagliflozin: Phase III data

The double-blind, placebo-controlled, international Phase III CANTATA-D (DIA3006) trial in 1,284 Type II diabetics with inadequate glycemic control on maximally effective doses of metformin showed that once-daily 300 mg canagliflozin significantly reduced HbA1c from

Read the full 348 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers